More Videos
SPECIAL REPORT
MOST SHARED
- Garlic Price Rises Surpass Gold, Stocks in China
- New-Home Sales Jump 6.2% To Highest Level in Over Year
- S&P Stocks Trading at New 52-Week Highs
- Where Do Pardoned Turkeys Go?
- Judge Erases Couple's $525,000 Mortgage Payment
- The Executive Job Search
- US Mint to Suspend American Eagle Gold 1-Ounce Coins
- Salvation Army's Kettles Now Credit Card-Ready
- US Plans to Reduce Emissions By 17% Within Next Ten Years
- Consumer Mood Improves, But Anxiety Over Personal Finances
- 4 Thanksgiving Week Buys For Your Portfolio: Market Pros
- There's a 'Great Chance' For a Double-Dip Recession: Strategist
- Revenge of the Gangsta Nerds
- Will TCU See The "Flutie Effect?"
- Retail Earnings and Sales to Improve in Q4: Analyst
- Consumers Catching the Holiday Spirit
- It's Beginning To Look A Lot More Riskless
- Crescenzi: Claims Level Suggests End to Job Losses
- Hedge Funds Take Early Lead in Warren Buffett's 'Big Bet'
- AIG, Ex-CEO Greenberg Reach Pact to Settle Disputes
- Bank of America CEO Search May Extend Into 2010
- 'Cancer of Fraud' Permeates Health Care System: Critics
- US Mint to Suspend American Eagle Gold 1-Ounce Coins
- Judge Erases Couple's $525,000 Mortgage Payment
- For Many in US, It Will Be a Scaled-Down Holiday Season
- Where Do Pardoned Turkeys Go?
- Jobless Claims Below 500,000, Durable Orders Slip
- Activision Prepares to Double Dip on ‘Modern Warfare 2’
PHARMA'S MARKET VIDEO
RSS FEED
Pharma's Market
Text Size 
 |
CNBC.com |
More and more drug companies have been farming out an increasing amount of their research to firms like Charles River Labs and Covance. For example, Eli Lilly [LLY
Loading...
()
] and Covance [CVD
Loading...
()
] recently did an exclusive deal worth about a billion-and-a-half bucks over time. And CRL just opened up a new facility in China, has been expanding its square footage here in the U.S. and hiring a lot of people. But that was before the credit crisis.
To be sure, CRL says it's in good financial shape. The company has $213 million in cash and "a favorable debt to equity ratio". But this morning when CRL [CRL
Loading...
()
] reported its earnings it revealed that its pre-clinical lab business is taking a hit because small, cash-strapped biotechs, in particular, aren't spending as much money on that kind of research for the time being. Pre-clinical means that the work is done in the lab in Petri dishes and on animals, that a drug hasn't been tested yet on people. It's the earliest stage of pharmaceutical research.
That unit at CRL saw sales grow only 4.6 percent in the third quarter because of what the company called, "study slippage and delays as a result of pharmaceutical and biotechnology companies' restructuring and pipeline reprioritization and negative foreign currency translation." The downturn is so severe, though, that CRL had to cut its sales and earnings guidance for this year and that's why the stock in midday trading has lost more than a fifth of its value and hit a new intra-day low of $25.65. CVD shares are also being punished.
Charles River Labs Chairman and CEO Jim Foster says a lot of the work is being pushed out from this year to next. "They (clients) are continuing to outsource," Foster is quoted as saying, "but due to heightened cost controls and year-end budget constraints, are spending in a more measured way." For pharma, Foster says the problem is drug patent expirations. But for baby biotechs he specifically blames "the availability of funding."
Small biotech companies usually don't have a product on the market and little or no cash coming in, so they constantly have to control how much money they spend. And in times like these when credit and borrowing is extremely tight, especially for risky businesses, the biotechs have to earmark their cash for only the most promising and/or most advanced pipeline product(s) in development. That means a lot of stuff that hasn't entered the clinic yet is likely gonna fall by the wayside.
And that's how Charles River Labs got caught in the cross-current of the credit crunch.
More from CNBC.com
Questions? Comments?
Data is a real-time snapshot *Data is delayed at least 15 minutes